ABVX:EPA
Abivax SA
€77.15
arrow_downward
-0.64%(-0.50) 1D
Nov 6, 5:36:06 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€74.45
High
€77.15
Low
€73.80
Mkt. cap
6.84B
Avg. vol.
111.44K
Volume
161.37K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€74.45
High
€77.15
Low
€73.80
Mkt. cap
6.84B
Avg. vol.
111.44K
Volume
161.37K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
www.tmgm.com
·
13 hours ago
United States CFTC S&P 500 NC Net Positions up to $-129.4K from previous $-134.4K
富途牛牛
·
2 hours ago
JPMorgan: The momentum crash is a mid-cycle correction within the AI supercycle; maintains S&P 500 target at 8,000 points.
BigGo Finance
·
12 hours ago
Dow Falls Another 237 Points; AI Stocks Rebound but Rate-Hike Expectations Weigh
Investing.com
·
13 hours ago
S&P cuts Uganda outlook to stable on oil delays and widening fiscal deficit
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteabivax.com